A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

Summary

This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies. The main aims of the study are to check the safety of ASP388B and find the most suitable dose. This study will be in 2 parts. In Part 1, different small groups of people with solid tumors will receive lower to higher doses of ASP388B. Some groups will receive ASP388B by itself, and other groups will receive ASP388B with standard cancer therapies.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Locally Advanced or Metastatic Solid Tumors

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Astellas Pharma Global Development, Inc.

Last updated on ClinicalTrials.gov

September 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites